SPECIAL NOTICE
D -- FDA's Transparency Initiative - RFI
- Notice Date
- 11/22/2010
- Notice Type
- Special Notice
- NAICS
- 511210
— Software Publishers
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- RFI_22112010_Business_Intelligence
- Archive Date
- 1/6/2011
- Point of Contact
- Sherry Solodkova, Phone: 301-827-7165, Brendan McCarthy, Phone: 3018274680
- E-Mail Address
-
sherry.solodkova@fda.hhs.gov, Brendan.McCarthy@fda.hhs.gov
(sherry.solodkova@fda.hhs.gov, Brendan.McCarthy@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Compliance Matrix RFI Title: FDA's Transparency Initiative Request For Information (RFI) This Request for Information (RFI) is for information, planning and market research purposes only and shall not be construed as either a solicitation or obligation on the part of the Food and Drug Administration or its Centers. The purpose of this RFI is to help the FDA understand the market availability, technical characteristics, and functionality of solutions, tools, or products capable of satisfying the technical, functional, and/or operational characteristics described in this RFI. FDA will use this market research information to assess the market's capability to provide a comprehensive business intelligence platform that delivers a full range of sophisticated analytic and interactive reporting capabilities and an extensive data warehousing engine with high scalability and reliability, and performance that will allow the agency to implement its transparency-related efforts. FDA welcomes responses from all interested parties. FDA does not intend to make a selection decision or award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted or FDA's use of such information. Acknowledgment of receipt of responses will not be made, nor will respondents be notified of the outcome of the FDA's evaluation of the information received. Additionally, the FDA does not intend to hold discussions concerning this RFI with any interested parties. However, FDA reserves the right to contact vendors if additional information is required. The attached RFI documents contain additional information and instructions for submission of responses.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/RFI_22112010_Business_Intelligence/listing.html)
- Place of Performance
- Address: n/a, United States
- Record
- SN02331957-W 20101124/101122234159-37db47b25928aadbff61e5caa699b3ac (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |